Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open label, multicentre study, evaluating the safety, tolerability, efficacy, compliance and the acceptability of alkalising treatments at long-term in patients with cystinuria

Next Previous
Trial Profile

Open label, multicentre study, evaluating the safety, tolerability, efficacy, compliance and the acceptability of alkalising treatments at long-term in patients with cystinuria

Status: Withdrawn prior to enrolment
Phase of Trial: Phase II/III

Latest Information Update: 15 Mar 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Potassium bicarbonate/potassium citrate (Primary) ; Potassium bicarbonate; Potassium citrate; Sodium bicarbonate; Sodium citrate
  • Indications Cystinuria
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Advicenne

Most Recent Events

  • 08 Mar 2024 Planned End Date changed from 1 Aug 2022 to 1 Aug 2025.
  • 08 Mar 2024 Planned primary completion date changed from 1 Aug 2022 to 1 Jun 2025.
  • 08 Mar 2024 Planned initiation date changed to 1 May 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top